When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

“As more schools and districts invest in AI training, teachers are seeing practical use cases and gaining the confidence to ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

We explain how aluminium went from a luxury metal to a world changing material. In the 1800s it was more expensive than gold. New refining methods dropped the price from $1.200 per kilo to just $1.

Conspiracies might be fun to entertain. But the "big lie" tactic destroys your judgment and credibility. Find out why, and ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the best NASDAQ stocks under $10 to buy. As of December 15, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) has a ‘Hold’ or equivalent rating from ...

“We were able to causally link a specific brain pathway to a ‘brake’ on motivation when individuals face unpleasant tasks in ...

In a world where AI-driven bots can forge documents, create synthetic IDs and spoof biometric data, intentional friction is ...

Let's look at the pros and cons of going full AI to help you understand how the value and purpose of software development outsourcing will change in this new era of AI.

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Belle Lin: Welcome to Tech News Briefing. It's Tuesday, December 23rd. I'm Belle ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

One analyst tracking the biotech upgraded her recommendation on its shares. She now believes that they rate a buy, rather than a hold. 10 stocks we like better than Recursion Pharmaceuticals › An ...